Related Experiment Videos
ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy
Kensaku Miyake1, Nobuhiro Ibaraki, Yoko Goto
1Shohzankai Medical Foundation, Miyake Eye Hospital, Nagoya, Japan. miyake@spice.or.jp
Journal of Cataract and Refractive Surgery
|October 3, 2003
Summary
Antiglaucoma eyedrops can cause cystoid macular edema (CME) in pseudophakia. Preservatives in these drops, particularly benzalkonium chloride, intensify inflammation and prostaglandin synthesis, leading to this condition.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Cystoid macular edema (CME) is a known complication of antiglaucoma eyedrops in aphakic and pseudophakic eyes.
- The role of preservatives in antiglaucoma medications contributing to CME requires further elucidation.
Purpose of the Study:
- To investigate the incidence of CME in early postoperative pseudophakia.
- To compare the effects of preserved and nonpreserved antiglaucoma medications and their vehicles.
- To assess the cellular and molecular mechanisms underlying drug-induced maculopathy.
Main Methods:
- Review of 4 clinical and laboratory studies.
- Comparison of preserved latanoprost/timolol, nonpreserved timolol, and drug vehicles.
- Analysis of cellular morphological damage.
- Measurement of cytokine and prostaglandin (PG) synthesis indicators.
Main Results:
- Preserved latanoprost and timolol, and their preservative benzalkonium chloride, were associated with increased PG synthesis.
- The preservative component intensified postoperative inflammation.
- Morphological cell damage was observed.
Conclusions:
- Benzalkonium chloride in antiglaucoma eyedrops contributes to pseudophakic CME.
- The term "pseudophakic preservative maculopathy" is proposed for this condition.
- Understanding the role of preservatives is crucial for managing ocular inflammation post-surgery.